Background: TRIM29 belongs to the tripartite motif (TRIM) protein family. It has been reported to be a tumor suppressor or have oncogenic function in many cancer types. The aim of this study was to investigate whether downregulation of TRIM29 by small interfering ribonucleic acid (siRNA) could inhibit cell proliferation and invasion and increase chemosensitivity to cisplatin in human lung squamous cancer NCI-H520 cells in vitro. Methods: We transformed TRIM29 siRNA into NCI-H520 cells. Real time reverse transcriptase polymerase chain reaction and Western blotting assay were employed to determine TRIM29 messenger (m)RNA and protein expressions. MTT assay was used to determine the cell proliferation. Transwell invasion assay was used to determine the cell invasion. An Annexin V-propidium iodide (AnnV/PI) staining apoptosis test was used for detecting apoptosis. Results: TRIM29 siRNA could specifically and efficiently suppress TRIM29 expression at both mRNA and protein levels. Silencing of the TRIM29 by siRNA in NCI-H520 cells inhibited cell proliferation and invasion in vitro. TRIM29 knockdown resulted in chemosensitivity enhancement in NCI-H520 cells. Conclusion: Downregulation of TRIM29 can lead to potent antitumor activity and chemosensitizing effect in human lung squamous cancer NCI-H520 cells.
Introduction
Lung cancer is the leading cause of cancer-associated death worldwide. 1 Although treatment with surgery and chemotherapy has improved dramatically, there has been no great improvement in the rate of survival over the past years. 2 Therefore, a better understanding of the molecular mechanisms underlying lung cancer formation and progression should be helpful in developing more effective treatments for this disease.
TRIM29 is a member of the tripartite motif (TRIM) family. This family consists of at least 37 member proteins and is characterized by its unique structure: a RING (R), a B-box type 1 (B1) and B-box type 2 (B2), followed by a coiledcoil (CC) region. While some of the domains may be absent or present, TRIM29 contains the B1-B2-CC domains, but lacks the R domain. 3 The TRIM family has been implicated in a variety of cellular processes, including development and growth. TRIM29 has been reported to be upregulated and downregulated in some cancer types. This suggests that the function of TRIM29 may be dependent on different cellular context and molecular signaling pathways. 4 The involvement of TRIM29 with proliferation and tumoral progression has been reported in many cancer cells, such as multiple myeloma, colorectal, endometrial, breast, prostate, gastric, and pancreatic cancers. 5 TRIM29 is involved in a variety of cancers, however, its function can change, depending on the cell type, level of expression, posttranslational modification, and compartmentalization. Although TRIM29 has been implicated as a tumor suppressor in some types of breast and bone cancers, 6 it is also known to have oncogenic effects in gastric and pancreatic cancers. 4 Transfection of wildtype TRIM29 into osteosarcoma and breast cancer cell lines lacking detectable messenger ribonucleic acid (mRNA) and protein expression of TRIM29 results in suppression of colony-forming efficiency in soft agar, suggesting that TRIM29 can cause reversion of a malignant phenotype. In contrast, in vitro and in vivo studies in pancreatic cancer revealed that TRIM29 can increase proliferation and invasion through stabilization β-catenin and activation of Disheveled 2. 4 Although TRIM29 was shown to be overexpressed in lung cancer cells and has been implicated as playing important roles in the development of lung cancer, 7 the exact function of TRIM29 in lung cancer cell growth and progression is not fully understood.
RNA interference (RNAi) has been recently developed as a powerful tool to suppress the expression of specific gene products. 8 We used RNAi methods to suppress TRIM29 expression in NCI-H520 cells. Our results suggest that knockdown of TRIM29 reduced the proliferative and metastatic capacity of the human lung squamous cancer cell line NCI-H520, and could make NCI-H520 cells more sensitive to cisplatin therapy. Thus, TRIM29 may be a good molecular target in the treatment of human lung squamous cancer.
Materials and methods

Cell culture and small interfering ribonucleic acid (siRNA) transfection
Human lung squamous cancer cell line NCI-H520 was obtained from the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China. Cells were cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories Inc, Logan, UT, USA) in a humidified 5% CO2 atmosphere. The human TRIM29 specific small interfering ribonucleic acid (siRNA) was purchased from GenePharma Co Ltd (Shanghai, China). The sequences of the siRNA used were as follows: siRNA1: sense, 5′-GAGCUGC GCAAGUCCAUUUTT-3′, siRNA2: sense,5′-ACGGAGCU GUCAUUGCAAATT-3′, siRNA3:sense, 5′-GUGCAUUG AUGAGCAAUUATT-3′, Negative control siRNA: sense, 5′-UUCUCCGAACGUGUCACGUTT-3′. The siRNA transfection was performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in Opti-MEM (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The transfection reagent was removed after eight hours and the cells were harvested after 48 hours.
Real-time polymerase chain reaction (PCR) analysis
Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA) reagent according to the manufacturer's instructions. RNA was reverse-transcribed using an Omniscript RT kit (Tiangen, Beijing, China). Real time polymerase chain reaction (PCR) was performed with an ABI PRISM 7500 instrument (Applied Biosystems, Foster City, CA, USA) using SYBRGreen PCR reagents (Tiangen, Beijing, China); 18S was applied as an internal control. For each group, TRIM29 mRNA expression was corrected against 18S mRNA levels and the comparative threshold cycle number method was used to assess the relative quantification of gene expression.
Western blotting analysis
NCI-H520 cells were lysed with a radioimmunoprecipitation assay (RIPA, Pierce, Rockford, IL, USA) buffer that was supplemented with complete proteinase and phosphatase inhibitor cocktails (Roche, Basel, Switzerland). After centrifugation at 4°C, the supernatant was collected and protein concentration was measured using the bicinchoninic acid assay kit (Pierce, Rockford, IL, USA). Protein extracts (30 μg) were separated using 10% sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDS-PAGE), and then transferred onto nitrocellulose membranes (Schleicher & Schuell, Keene, NH, USA). The membranes were then blocked with five percent skim milk and incubated with specific primary antibodies overnight at 4°C followed by speciesspecific secondary antibody. Primary antibodies for TRIM29 (1:200 dilution) and β-actin (1:2000 dilution) were from Cell Signaling Technology (Beverly, MA, USA). Immunoreactive material was detected by the enhanced chemiluminescence technique (Amersham, Little Chalfont, Buckinghamshire, UK).
MTT assays for cell proliferation
Cell proliferation ability was assessed by the MTT assay. Cells treated with TRIM29 siRNA, scrambled control siRNA or with medium alone were plated at 5 × 10 3 cells per well on a 96-well plate. At various time-points, 20 μl of sterile MTT was added to each well at a final concentration of 5 mg/mL. Cells were further incubated at 37°C for four hours. Dimethyl sulfoxide (DMSO) (150 μl) was then added to stop the reaction. The absorbance of each well was determined at 490 nm. Each experiment was performed independently three times.
Annexin V-propidium iodide (AnnV/PI) staining apoptosis test
Cells in each well were harvested after siRNA transfection and cisplatin (5 μg/mL) treatment. Flowcytometric analysis was performed to detect apoptosis using a FACScan flow cytometer (BD, San Jose, CA, USA) in accordance with the manufacturer's protocol.
Transwell invasion assay
BioCoat transwell chambers (Corning Costar, Cambridge, MA, USA) with uncoated porous inserts (pore size 8 μm) were used in cell invasion assay. The upper surface of the transwell filters was coated with Matrige Matrix (BD Biosciences, San Jose, CA, USA). Cells were harvested in 200 μl of serum free RPMI-1640 medium and added to the upper compartment of the chamber. After 24 hours incubation at 37°C in a five percent CO2 incubator, cells that had migrated across the matrigel into the pores of the inserted filter were fixed with 90% methanol, stained with hematoxylin, mounted, and dried at 80°C for 30 minutes. The number of cells was counted under the microscope from three randomly selected visual fields (magnification ×200). The experiments were performed independently three times.
Statistical analysis
SPSS 13.0 (SPSS, Chicago, IL, USA) software was used for analyses. Results are expressed as mean ± standard deviation (SD). The statistical significance of the results was determined using the Student's t-test. P < 0.01 indicated a statistically significant difference.
Results
siRNA targeting tripartite motif (TRIM)29 knocks down TRIM29 expression
After siRNA interference TRIM29 for 48 hours, TRIM29 mRNA and protein were measured by quantitative real-time PCR and Western blotting, respectively. In our assay, three TRIM29 siRNAs (TRIM29 siRNA1, TRIM29 siRNA2, TRIM29 siRNA3) were used to suppress TRIM29 expression, Compared with TRIM29 siRNA1 and 2, TRIM29 siRNA3 could mostly specifically and efficiently suppress TRIM29 expression at both mRNA and protein levels (Fig 1) . Therefore, we chose TRIM29 siRNA3 to fulfil our assay.
siRNA TRIM29 inhibits NCI-H520 cell proliferation
We used an MTT assay kit to evaluate the effect of TRIM29-RNAi on cell growth. As shown in Figure 2 , the growth curves of TRIM29 knockdown cells were significantly lower than those of the control cells for the five days of incubation.
Downregulation of TRIM29 expression inhibits cell invasion
We studied the effect of TRIM29 knockdown on the invasion of NCI-H520 cells. The results showed that invasion was significantly inhibited in the TRIM29 knockdown cells compared with the untreated group, or the siCONTROL group (Fig 3) .
Knockdown of TRIM29 expression increases sensitivity of NCI-H520 cells to chemotherapy
We examined the effect of TRIM29 suppression on NCI-H520 cell apoptosis with flow cytometric analysis. As shown in Figure 4a and c, after transfection with TRIM29 siRNA at 48 hours, cell apoptosis was induced. Furthermore, cell apoptosis was increased when cells were treated with 5 μg/mL cisplatin (Fig 4b and d) .
Discussion
Lung cancer is one of the most common human cancers worldwide. According to the World Health Organization GLOBOCAN project, 1.6 million new cases of lung cancer, accounting for 12.7% of the world's total cancer incidence, were diagnosed in 2008. 9 Despite advances in surgical and chemotherapy techniques, the survival rate of lung cancer is far from satisfactory. To further improve the clinical outcome of lung cancer patients, identifying novel and effective antitumor strategies, such as targeted therapy, will be crucial.
TRIM29, located at chromosome 11q22-23, encodes a 588 amino acid protein with multiple zinc-finger motifs and an adjacent leucine-zipper motif. TRIM29 has been reported to be overexpressed in variety of different cancers, including lung, bladder, colorectal, ovarian and endometrial cancers, and multiple myeloma. [10] [11] [12] [13] [14] [15] [16] Conversely, it has been reported to be diminished in some cancers. [17] [18] [19] [20] These results suggest that the function of TRIM29 may vary depending upon the tissue origin of the neoplasm. A recent study found TRIM29 protein was upregulated in NSCLC tissues compared to the adjacent normal tissues and correlated with clinic pathological factors and prognosis. 7 In our study, we found that TRIM29 mRNA and protein were highly expressed in NCI-H520 cells. These results are consistent with previous reports. Inhibiting specific gene expression by RNAi has become an important method of cancer treatment. 21, 22 We employed RNAi technology to downregulate TRIM29 expression in this cell line. After transfection with the TRIM29 siRNA, the mRNA and protein expressions decreased significantly compared with control group. These results indicated that TRIM29 siRNA could suppress the expression of TRIM29 effectively and specifically in NCI-H520 cells.
Previous studies have found that TRIM29 expression was associated with cell proliferation and tumor growth. Wang et al. discovered that TRIM29 promoted pancreatic cancer cell proliferation in vitro and enhanced tumor growth and metastasis in vivo. 4 Yuan et al. reported that TRIM29 increases cancer cell proliferation via inhibition of p53 nuclear activities. 23 Sho et al. proved that TRIM29 functions as an oncogene that promotes tumor growth. 24 Jiang et al. found that TRIM29 plays an important role in promoting colorectal cancer progression and downregulation of TRIM29 inhibited tumor cell proliferation in vitro. 25 To further investigate the functions of TRIM29 in lung cancer, we examined the NCI-H520 cells transfected with TRIM29 siRNA. The proliferation rate was analyzed by MTT assay. We found that suppressing the expression of TRIM29 in NCI-H520 cells would suppress cell proliferation compared with control group. This result suggests that TRIM29 expression influences proliferation rates in NCI-H520 cells.
A recent report described a correlation between TRIM29 expression with poor histological grade, tumor node metastasis (TNM) stage, and lymph node metastasis in lung squamous cell carcinoma tissues. 7 We further studied the effect of TRIM29 suppression on the metastatic capacity of NCI-H520 cells. The assays showed that downregulation of TRIM29 significantly reduced NCI-H520 cell invasiveness compared with the control group. Therefore, there is a relationship between TRIM29 and the invasion ability in human lung squamous cancer cells. TRIM29 has previously been reported to be involved in cancer metastasis in other cell lines. Lai et al. discovered that both TRIM29 mRNA and protein expression in esophageal squamous-cell carcinoma (ESCC) tissues were significantly correlated with tumor differentiation, stage, and lymph node metastasis. 26 Jiang et al. reported that the expression of TRIM29 was significantly associated with the depth of tumor invasion, lymph node metastasis, and distant metastasis in colorectal cancer. 25 Early in 2007, Kosaka et al. proved that increased TRIM29 expression was markedly associated with tumor invasion and lymph node metastasis in gastric cancer. 11 Our results are consistent with previous research that has shown that TRIM29 expression can influence the extent of tumor invasion and lymph node metastasis in some cancers.
Cisplatin is usually used for the treatment of several types of cancer and it primarily acts by causing DNA damage. However, the ability of cancer cells to become resistant to cisplatin remains a significant impediment to successful chemotherapy. 9 Previous studies have found a number of mechanisms for cisplatin resistance. 27 However, exact mechanisms are needed to find new targets to prevent drug resistance.
Early in 1989, TRIM29 was found to suppress the sensitivity to ionizing radiation (IR). 28 Yuan et al. discovered that TRIM29 expression leads to resistance to ionizing radiation, whereas silencing of TRIM29 expression increases sensitivity to ionizing radiation in cell cultures. 23 Another study reported that TRIM29 participates in the survival of differentiating keratinocytes, which are more and more exposed to ultraviolet (UV)B and pro-death stimuli. 29 Cisplatin, ionizing radiation, and UVB could induce the DNA damage response process by causing cell apoptosis. Based on this mechanism and previous research, we postulate that inhibition of TRIM29 expression with siRNA could increase chemosensitivity to cisplatin. As expected, in our study we found that knockdown of TRIM29 enhanced apoptosis induced by cisplatin and made cells more sensitive to cisplatin treatment.
Conclusion
Our data have shown that downregulation of TRIM29 by siRNA inhibited the proliferation and invasion of NCI-H520 cells and increased chemosensitivity to cisplatin. These findings suggest that TRIM29 may have a wide therapeutic application in the treatment of human lung squamous cancer.
